Baxter International Inc.
BAX Healthcare Medical - Instruments & Supplies NYSE
$17.88
$-0.72 (-3.87%)
Open: $18.33 | High: $18.37 | Low: $17.54 | Prev Close: $18.60
Market Cap: $9.20B
Volume: 6.0M | Avg: 9.6M
Last updated: March 06, 2026 at 08:00 PMInvestment Rating
Sell
Overall Score: 40/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 385
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | -10.46 |
| P/B Ratio | 1.50 |
| P/S Ratio | 0.82 |
| EPS | $-1.71 |
| Beta | 0.55 |
| Shares Outstanding | 514.49M |
| 52-Week High | $37.74 |
| 52-Week Low | $17.40 |
| SMA 50 | $20.16 |
| SMA 200 | $23.31 |
| Dividend Yield | 2.01% |
| Annual Dividend | $0.36 |
| Next Earnings | April 30, 2026 01:30 PM ET |
Financial Ratios
| Gross Margin | 30.1% |
| Operating Margin | -2.7% |
| Net Margin | -8.5% |
| ROE | -13.8% |
| ROA | -4.8% |
| Debt/Equity | 1.60 |
| Current Ratio | 2.31 |
| Quick Ratio | 1.56 |
Balance Sheet
| Total Assets | $20.05B |
| Total Liabilities | $13.95B |
| Total Equity | $6.13B |
|
|
|
| Cash | $1.97B |
| Total Debt | $10.00B |
| Net Debt | $8.04B |
Income Statement
| Revenue | $11.24B |
| Gross Profit | $3.38B |
| Operating Income | $-308,000,000 |
| Net Income | $-957,000,000 |
|
|
|
| EBITDA | $766.00M |
| Revenue/Share | $21.88 |
Cash Flow
| Operating CF | $845.00M |
| CapEx | $522.00M |
| Free Cash Flow | $323.00M |
|
|
|
| Book Value/Share | $11.87 |
| Tangible Book/Share | $-6.22 |
| Equity/Share | $11.92 |
Technical Indicators
| RSI (14) | 34.15 Neutral |
| MACD |
-0.44
Signal: -0.06
|
| Volatility | 61.58% |
| Trading Signal | Bearish |
Performance & Returns
| 1 Year | -43.18% |
| Sharpe Ratio | -1.36 Poor |
| Volatility (Ann.) | 47.03% High Risk |
| BAX (1Y) | -43.18% |
| S&P 500 (1Y) | +13.03% |
| Alpha (Excess Return) | -56.22% |
Sector Comparison (Healthcare)
| Metric | BAX | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | -10.46 | 28.39 | 0% |
| P/B Ratio | 1.5 | -19.55 | 25% |
| ROE (%) | -13.78% | -9.02% | 17% |
| Net Margin (%) | -8.51% | 9.66% | 4% |
| Stock Score | 385 | 546.0 | 0% |
| 1Y Return (%) | -43.18 % | +9.15 % | 4% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BAX | $17.88 | $18.82 | $19.45 | $20.21 | $20.14 | $23.25 | 34.15 | -0.44 | 61.58% | 6032130 | Strong Short | Bearish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the BAX stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| BAX | Baxter International Inc. (BAX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript | Neutral | seekingalpha.com | Read More |
| BAX | Sticking With Baxter At The Lows | Neutral | seekingalpha.com | Read More |
| BAX | Baxter International Inc. (BAX) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript | Neutral | seekingalpha.com | Read More |
| BAX | Artisan Value Income Fund Q4 2025 Portfolio Activity | Neutral | seekingalpha.com | Read More |
| BAX | Baxter International Inc. (NYSE:BAX) Receives Average Recommendation of “Reduce” from Brokerages | Neutral | defenseworld.net | Read More |
Recent Insider Trading
No recent insider trading data available for BAX
Company Information
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
| CEO | Andrew Hider |
| Employees | 38000 |
| Country | US |
| IPO Date | 1981-10-27 |
| Exchange | NYSE |
| Website | https://www.baxter.com |
| Sector | Healthcare |
| Industry | Medical - Instruments & Supplies |
Similar Stocks (Healthcare - Medical - Instruments & Supplies)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category